Neumora Therapeutics Target Price

Analysts' average 12-month price target for Neumora Therapeutics is $4.5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$1.5

Average Target Price

$4.50

200% upside

2 analysts in the last 4 months

High: $5 | Low: $4

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-13	RBC CapitalBrian Abrahams	$5	233.3% upside
2026-06-18	Mizuho Securities	$4	166.7% upside
2026-01-12	Leerink PartnersMarc Goodman	$8	433.3% upside
2026-01-05	Mizuho SecuritiesGraig Suvannavejh	$6	300% upside
2025-12-01	RBC Capital	$7	366.7% upside
2025-10-28	Needham	$8	433.3% upside
2025-03-07	Stifel Nicolaus	$2	33.3% upside
2025-01-02	RBC CapitalBrian Abrahams	$4	166.7% upside
2024-07-22	NeedhamAmi Fadia	$23	1433.3% upside
2024-07-08	Mizuho SecuritiesGraig Suvannavejh	$20	1233.3% upside
2024-06-17	RBC CapitalBrian Abrahams	$29	1833.3% upside
2024-03-13	RBC CapitalBrian Abrahams	$31	1966.7% upside
2023-10-10	Stifel NicolausPaul Matteis	$26	1633.3% upside
2023-10-10	RBC CapitalBrian Abrahams	$24	1500% upside

Neumora Therapeutics (NMRA) FAQ

The latest target price for NMRA is $4.5. Investors often review this figure alongside Neumora Therapeutics's historical trend and sector peers before judging valuation or financial health.

Neumora Therapeutics trades near $1.5 while the consensus target sits at $4.5 (200.0% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting NMRA's target price ($4.5), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.